FindTrial
Sign In

To study the effects of nutritional supplementation of extremely active resveratrol (XAR) in healthy human individuals.

A single centre, open label study to assess the safety and efficacy of oral herbal capsule to improve HDL, DHEA and insulin level in healthy volunteers. - SSEHH

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/09/009694
Enrollment
100
Registered
2017-09-11
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: XAR ( Extremely active resveratrol): Resveratrol 10.5 mg dose oral, thrice a day for thirty days Control Intervention1: not applicable: not applicable

Sponsors

Epigeneres Biotech Pvt Ltd
Lead Sponsor
Epigeneres Biotech Pvt Ltd
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. Healthy volunteers of age 20 to 55 years of either sex who are not involved in any regular medication or supplementation. 2. Subjects having HDL level, normal, lower and less than lower range at screening visit. 3. Subjects who are willing to give their written informed consent and comply with the protocol requirements.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
To determine the efficacy of XAR Capsule 500mg (containing 10.5 mg of extremely active resveratrol) on HDL, DHEA and insulin level.Timepoint: 30 days—

Secondary

MeasureTime frame
To determine the efficacy of XAR Capsule on Total cholesterol, Very Low Density Lipoprotein, Low density lipoprotein, Triglyceride, Testosterone, Thrombotic, renal profile, Homocysteine, Estradiol and Anti-Mullerian Hormone. The effect of XAR will be analyzed on the expression of stem cell genes and other genes in the peripheral blood cells.Timepoint: 30 days—

Countries

India

Contacts

Public ContactDr Sagar Chhabria

Epigeneres Biotech Pvt. Ltd.

sagar@epigeneres.com9869820610

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026